JP2002538170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002538170A5 JP2002538170A5 JP2000602303A JP2000602303A JP2002538170A5 JP 2002538170 A5 JP2002538170 A5 JP 2002538170A5 JP 2000602303 A JP2000602303 A JP 2000602303A JP 2000602303 A JP2000602303 A JP 2000602303A JP 2002538170 A5 JP2002538170 A5 JP 2002538170A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administration
- antigen
- binding fragment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000006673 asthma Diseases 0.000 description 9
- 229960000598 infliximab Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 229940116176 remicade Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26095399A | 1999-03-02 | 1999-03-02 | |
| US09/260,953 | 1999-03-02 | ||
| US46569199A | 1999-12-17 | 1999-12-17 | |
| US09/465,691 | 1999-12-17 | ||
| PCT/US2000/005163 WO2000051637A1 (en) | 1999-03-02 | 2000-03-01 | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010195818A Division JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002538170A JP2002538170A (ja) | 2002-11-12 |
| JP2002538170A5 true JP2002538170A5 (https=) | 2010-10-28 |
Family
ID=26948290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000602303A Pending JP2002538170A (ja) | 1999-03-02 | 2000-03-01 | 喘息の治療における抗−ＴＮＦα抗体 |
| JP2010195818A Pending JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010195818A Pending JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20010021381A1 (https=) |
| EP (1) | EP1159003B1 (https=) |
| JP (2) | JP2002538170A (https=) |
| AT (1) | ATE488250T1 (https=) |
| AU (1) | AU756677B2 (https=) |
| CA (1) | CA2364026C (https=) |
| DE (1) | DE60045240D1 (https=) |
| DK (1) | DK1159003T3 (https=) |
| PT (1) | PT1159003E (https=) |
| WO (1) | WO2000051637A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| WO2004071527A1 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| KR20090078349A (ko) | 2006-10-12 | 2009-07-17 | 제넨테크, 인크. | 림포톡신-알파에 대한 항체 |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
| MX2010012473A (es) | 2008-05-23 | 2011-02-23 | Siwa Corp | Metodos, composiciones y aparato para facilitar la regeneracion. |
| DK2676137T3 (en) * | 2011-02-17 | 2015-01-19 | Nestec Sa | TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS |
| CN107001459B (zh) | 2014-09-19 | 2021-11-23 | Siwa有限公司 | 用于治疗炎症和自身免疫紊乱的抗age抗体 |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| PT3337829T (pt) | 2016-02-19 | 2020-02-10 | Siwa Corp | Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga) |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CN115804821B (zh) * | 2022-12-19 | 2024-05-14 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822776A (en) * | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US6419927B1 (en) * | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
| US6309640B1 (en) * | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| EP0288088B1 (en) * | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
| US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
| US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| EP1097945B1 (en) * | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| DE4139733A1 (de) * | 1991-11-28 | 1993-06-03 | Schering Ag | Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren |
| AU5152293A (en) * | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
| EP0671936A1 (en) * | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
| GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| US20050260201A1 (en) * | 1993-01-29 | 2005-11-24 | Centocor, Inc. | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins |
| ES2159529T5 (es) * | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
| SE9302490D0 (sv) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
| GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| GB9702088D0 (en) * | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| TR199902562T2 (xx) * | 1997-04-15 | 2000-02-21 | Farmaceutisk Laboratorium Ferring A/S | De�i�tirilmi� TNF alfa molek�lleri |
| EP0980258A1 (en) * | 1997-05-12 | 2000-02-23 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
-
2000
- 2000-03-01 DK DK00912065.0T patent/DK1159003T3/da active
- 2000-03-01 WO PCT/US2000/005163 patent/WO2000051637A1/en not_active Ceased
- 2000-03-01 AT AT00912065T patent/ATE488250T1/de active
- 2000-03-01 CA CA2364026A patent/CA2364026C/en not_active Expired - Fee Related
- 2000-03-01 DE DE60045240T patent/DE60045240D1/de not_active Expired - Lifetime
- 2000-03-01 EP EP00912065A patent/EP1159003B1/en not_active Expired - Lifetime
- 2000-03-01 JP JP2000602303A patent/JP2002538170A/ja active Pending
- 2000-03-01 AU AU33861/00A patent/AU756677B2/en not_active Ceased
- 2000-03-01 PT PT00912065T patent/PT1159003E/pt unknown
-
2001
- 2001-01-12 US US09/759,412 patent/US20010021381A1/en not_active Abandoned
- 2001-08-28 US US09/942,075 patent/US20020119152A1/en not_active Abandoned
-
2006
- 2006-03-02 US US11/366,724 patent/US20060222646A1/en not_active Abandoned
-
2010
- 2010-09-01 JP JP2010195818A patent/JP2011006464A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002538170A5 (https=) | ||
| DE69931377T2 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
| US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| AU2008251943B2 (en) | Humaneered anti-factor B antibody | |
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| JP4851645B2 (ja) | 抗−プロカルシトニン抗体、その調製および使用 | |
| US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
| Hamelmann et al. | Interleukin (IL)-5 but Not Immunoglobulin E Reconstitutes Airway Inflammation and Airway Hyperresponsiveness in IL-4–Deficient Mice | |
| WO2002011677A2 (en) | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists | |
| JP2002539072A5 (https=) | ||
| JP2004534513A5 (https=) | ||
| CN103282384A (zh) | 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 | |
| オオグシフミタカ et al. | Autoantibodies to IL-1α in sera from rapidly progressive idiopathic pulmonary fibrosis | |
| CN117603358B (zh) | 一种广谱新型冠状病毒的双特异性抗体 | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| JPH06500323A (ja) | ウイルス性感染の治療方法 | |
| US20070048318A1 (en) | Method for treating psoriasis | |
| CN1189210C (zh) | Cb与生物活性多肽的偶联物及其医药用途 | |
| CA2730328C (en) | Immunogenic escherichia coli heat stable enterotoxin | |
| WO2005042028A2 (en) | Il-13 conjugated to an immunogen and uses thereof | |
| Wolff et al. | Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity | |
| ES2357749T3 (es) | Anticuerpos anti-tnf alfa en la terapia del asma resistente a esteroides. | |
| US5674493A (en) | Compositions and methods for targeting cells with A2R and A2R monoclonal antibodies | |
| ES2256579T3 (es) | Anticuerpos que estimulan la produccion de 1l-1ra. | |
| US20210340226A1 (en) | Human medical prophylaxis of coronaviridae pathogenic infection by topical application of immune coronaviridae immunoglobulin a |